Bofanglutide
Efficacy and Safety of GZR18 Every 2 Weeks Versus Tirzepatide and Placebo in Obese or Overweight Participants
Gan & Lee Pharmaceuticals · Phase 2 · Completed · Enrollment 326
Participants reaching threshold, %
Source: Cited trial source. The denominator is the source figure, when it states one.
No selected arm reports a responder percent.
Show as table
| Arm | ≥5% | ≥10% | ≥15% | ≥20% |
|---|---|---|---|---|
| 24 mg GZR18 group | n/r | n/r | n/r | n/r |
| 36 mg GZR18 group | n/r | n/r | n/r | n/r |
| 48 mg GZR18 group | n/r | n/r | n/r | n/r |
| Tirzepatide group | n/r | n/r | n/r | n/r |
Not shown
- 24 mg GZR18 group: endpoint not reported
- 36 mg GZR18 group: endpoint not reported
- 48 mg GZR18 group: endpoint not reported
- Tirzepatide group: endpoint not reported